Related Experiment Videos
Renagel: reducing serum phosphorus in haemodialysis patients
1GelTex Pharmaceuticals Inc., Waltham, MA 02451, USA.
Hospital Medicine (London, England : 1998)
|October 26, 2000
Abstract:
Approximately half of all dialysis patients experience persistent hyperphosphataemia, which causes significant problems. Renagel is a calcium-free, aluminium-free phosphate binder which reduces serum phosphorus in haemodialysis patients by reducing absorption of dietary phosphorus. This article reviews the management of hyperphosphataemia and presents some Renagel clinical trial data.